Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?

Vitale A, Boccagni P, Kertusha X, Zanus G, D'Amico F, Lodo E, Pastorelli D, Ramirez Morales R, Lombardi G, Senzolo M, Burra P, Cillo U.

Transplant Proc. 2012 Sep;44(7):1989-91. doi: 10.1016/j.transproceed.2012.06.046.

PMID:
22974889
2.

Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.

Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, Düber C, Schuchmann M, Otto G, Galle PR, Wörns MA.

Dig Liver Dis. 2012 May;44(5):432-7. doi: 10.1016/j.dld.2011.12.009.

PMID:
22265328
3.

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.

J Clin Gastroenterol. 2009 May-Jun;43(5):489-95. doi: 10.1097/MCG.0b013e31818ddfc6.

PMID:
19247201
4.

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.

Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B.

Liver Transpl. 2012 Jan;18(1):45-52. doi: 10.1002/lt.22434.

5.

Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.

Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK.

Jpn J Clin Oncol. 2010 Aug;40(8):768-73. doi: 10.1093/jjco/hyq055.

PMID:
20494947
6.

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.

Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M.

Oncologist. 2009 Jan;14(1):70-6. doi: 10.1634/theoncologist.2008-0191.

7.
8.

Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.

Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cordone G, Gentiluomo M, Belli LS.

Eur J Gastroenterol Hepatol. 2013 Feb;25(2):180-6. doi: 10.1097/MEG.0b013e328359e550. Review.

PMID:
23044808
9.

Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.

Woo HY, Heo J, Yoon KT, Kim GH, Kang DH, Song GA, Cho M.

Scand J Gastroenterol. 2012 Jul;47(7):809-19. doi: 10.3109/00365521.2012.683040.

PMID:
22563643
10.

Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.

Rimassa L, Santoro A.

Expert Rev Anticancer Ther. 2009 Jun;9(6):739-45. doi: 10.1586/era.09.41.

PMID:
19496710
11.

Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study.

Teng CL, Hwang WL, Chen YJ, Chang KH, Cheng SB.

World J Surg Oncol. 2012 Feb 17;10:41. doi: 10.1186/1477-7819-10-41.

12.

Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.

Saidi RF, Shah SA, Rawson AP, Grossman S, Piperdi B, Bozorgzadeh A.

Transplant Proc. 2010 Dec;42(10):4582-4. doi: 10.1016/j.transproceed.2010.09.147.

PMID:
21168742
13.

Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.

Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Dharancy S, Boleslawski E, Truant S, Pruvot FR, Hebbar M, Ernst O, Mathurin P.

Aliment Pharmacol Ther. 2011 Nov;34(10):1193-201. doi: 10.1111/j.1365-2036.2011.04860.x.

14.

Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.

Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Sakata K, Matsugaki S, Kajiwara M, Fukuizumi K, Tajiri N, Matsukuma N, Sakai T, Ono N, Yano Y, Koga H, Kurogi J, Takata A, Sumie S, Satani M, Yamada S, Niizeki T, Aino H, Iwamoto H, Torimura T, Sata M.

Oncology. 2013;84(2):108-14. doi: 10.1159/000342650.

PMID:
23147476
15.

Sorafenib: a review of its use in advanced hepatocellular carcinoma.

Keating GM, Santoro A.

Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. Review.

PMID:
19228077
16.

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R.

Oncologist. 2009 Jan;14(1):95-100. doi: 10.1634/theoncologist.2008-0185. Review.

17.

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K.

Cancer Sci. 2008 Jan;99(1):159-65.

18.

[Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].

Xu L, Li P, Lin XJ, Yuan YF, Zhang YQ, Chen MS.

Zhonghua Zhong Liu Za Zhi. 2009 Jan;31(1):58-61. Chinese.

PMID:
19538872
19.

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.

J Clin Oncol. 2006 Sep 10;24(26):4293-300.

PMID:
16908937
20.

Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.

Wörns MA, Schuchmann M, Düber C, Otto G, Galle PR, Weinmann A.

Oncology. 2010;79(1-2):85-92. doi: 10.1159/000320363.

PMID:
21071995
Items per page

Supplemental Content

Support Center